Enanta Pharmaceuticals

ENTA

Biotechnology · Healthcare

Price

$13.47

+0.34 (+2.59%)

Market Cap

$391.7M

Exchange

NASDAQ

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Good

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+5.8% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 20.2M (2021) → 21.3M (2025)

Winston Score History

The full picture

Enanta Pharmaceuticals is a small biotech company that discovers and develops drugs to treat viral infections and liver diseases. The company previously helped create a key component of AbbVie's hepatitis C treatment and is now focused on developing antiviral therapies for conditions like respiratory syncytial virus (RSV) and other infectious diseases. It is headquartered in Watertown, Massachusetts.

Enanta earns money primarily through royalties from its collaboration with AbbVie on hepatitis C drugs, along with milestone payments from partnerships. As a clinical-stage company, it spends heavily on research and development, resulting in significant operating losses. With a market cap around $400 million, Enanta is a small-cap biotech that relies on its expertise in chemistry-driven drug design as a competitive advantage. The company's future largely depends on the success of its pipeline candidates in clinical trials, and failure to advance these programs could put significant pressure on its financial position.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-21.6% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+22.1% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$107M/ year

↓ Declining (-19% vs prior year)

163.4% of revenue

9.1x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

5.1%ownership

↓ Declining

Insider ownership declining — could be dilution or selling

Cash Runway

~5 years

$190M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

$190M cash & investments at current burn rate

Revenue declining

Enanta Pharmaceuticals's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

100.0%

Premium pricing power — 100.0% gross margin

Profit after running costs

Operating Margin

-120.0%

Losing money on operations — -120.0%

Return on the money invested

ROCE

-58.1%

Weak — -58.1% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+0.7%

Nearly flat sales (+0.7% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

7/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-56.6%

Burning cash (-56.6%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial